GITMO’s Post

🌱 𝗡𝗲𝗽𝗵𝗿𝗼𝗸𝗶𝘁: 𝗖𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝗛𝗮𝗯𝗶𝘁𝘀, 𝗜𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗟𝗶𝘃𝗲𝘀! 🌱 🧪 Take it with a grain of salt, but one of the lessons taught to me by Mokhtar Chawki, the man who taught me the little I know about dialysis, whom I salute very kindly, is the following: "𝘋𝘪𝘢𝘭𝘺𝘴𝘪𝘴 𝘪𝘴 𝘢 𝘤𝘩𝘳𝘰𝘯𝘪𝘤 𝘱𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺, 𝘴𝘰 𝘭𝘦𝘢𝘳𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘤𝘦 Olivier, 𝘣𝘦𝘤𝘢𝘶𝘴𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴, 𝘤𝘢𝘳𝘦𝘨𝘪𝘷𝘦𝘳𝘴, 𝘢𝘯𝘥 𝘵𝘩𝘦𝘪𝘳 𝘩𝘢𝘣𝘪𝘵𝘴, 𝘢𝘭𝘴𝘰 𝘢𝘳𝘦." Improving vascular access management in dialysis involves changing gestures, practices, and deeply rooted habits. It requires time for testing and education for all stakeholders. We did this with Ettwiller Yannick from Theramed SA, whom I thank for his commitment to promoting the NEPHROKIT range in Switzerland. Do you want to know more about the positive impact that NEPHROKIT products can have on your connection and disconnection protocols or the protection of CVCs, in Switzerland or elsewhere (we are now present in more than 25 countries)? 🌍 Contact me by PM or by email o.valentin@nephrokit.fr and I will do what is necessary to organize these free trials as quickly as possible. 📧 Although present in more than 25 countries, we are looking for partners in many countries: if you are a distributor of dialysis consumables, passionate about vascular access, and active in England, Australia, South Africa, Croatia, Poland, Romania (but I can't name them all), then contacting me might not be a waste of time. 🌐 💡 NEPHROKIT: We constantly innovate to improve hemodialysis patients' quality of care and life. 🏭 All NEPHROKIT devices are made in France by GERGONNE INDUSTRIE - THE ADHESIVE SOLUTION . #dialysis #hemodialysis #vascular #access #vascularaccess #nephrologist #nurses #patients #patientcare #coagulation #fistula #dressing #hemostatic #patch #mozaik #wearenephrokit #wearegergonne #madeinfrance Medival S.r.l. Bionet Medical S.L. IVA Medical Hemotech Belux Bernas Médical Spirel AB Scan-Med A/S Denmark Scan-Med / NorDiaTech New EpiMed MEDANS OY Majestic Medical & Tech. Supplies GenaMed Wissam Hassanieh Imad Hamade BIOMEDICA CS

𝐈𝐧𝐭𝐫𝐚𝐨𝐜𝐮𝐥𝐚𝐫 𝐋𝐞𝐧𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐰𝐨𝐫𝐭𝐡 $6.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029, 𝐰𝐢𝐭𝐡 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 6.3% 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dvjeyeee The market for intraocular lenses (IOLs) is significantly driven by the world's aging population, which is growing at an accelerated rate. The incidence of age-related eye diseases, especially cataracts, increases sharply as life expectancy increases. The need for more cataract surgeries due to this aging population has increased demand for the IOLs placed during these procedures. Beyond simply cataract procedures, there is a spike in demand for IOLs. Growth in the market is further supported by new applications, including as IOLs for treating age-related macular degeneration (AMD) and presbyopia (age-related near vision loss). 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Alcon Johnson & Johnson | Vision Carl Zeiss Meditec Systems Hoya Vision Care  Bausch + Lomb  STAAR Surgical  Santen Pharmaceutical NIDEK USA. Lenstec, Inc.  BeaverVisitec International BVI Ophtec SAV-IOL Appasamy Associates Atia Vision Vision Biotech Teleon Omni Lens Pvt Ltd EyeKon Medical, Inc.  HumanOptics Holding AG  Hanita Lenses Ltd. EXCELLENT HI-CARE PRIVATE LIMITED ADVIN HEALTH CARE

𝐑𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $49.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 Download PDF Brochure @ https://lnkd.in/dPnCniRW The global 𝐫𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐦𝐚𝐫𝐤𝐞𝐭, 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 $16.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023, 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $49.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 25.1%. The global market is expected to benefit from the focus on #personalizedmedicines. Precision medicine is an approach to medical treatment that tailors therapeutics, and interventions for individual patients or a subpopulation based on their unique genetic, environmental, and lifestyle characteristics. the 𝐅𝐃𝐀 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 12 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬, 𝐫𝐞𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐢𝐧𝐠 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 34% of all newly approved therapeutic molecular entities. Personalized treatments account for at least a quarter of new drug approvals since 2015. Moreover, five new gene or #cellbased therapies were approved in 2022. These include treatment of rare #geneticdisorders with few other treatment options – #betathalassemia, #hemophiliaB, and cerebral adrenoleukodystrophy, refractory multiple #myeloma, and certain types of non-muscle invasive #bladdercancer. 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: Bubolo Medical   Biopico Systems INC      Mainz Clinic      Source Of Health      The Institute of Human Mechanics      Center for Traditional Medicine P.C.      CJ PARTNERS Inc.      ORA ORTHOPEDICS, PC      Pacific Pain and Wellness Group      Colorado Medical Solutions      iHeart Japan Corporation      DM Capital  Medical Magnus Clinic      Forest Hills Lab    Pacific Coast Sports Medicine      Research Institute for Complex Issues of Cardiovascular Diseases SB RAMS      Levitas Clinic      Vitalogy Wellness Center   Dr. Ed Nash, Progressive Pain & Rehabilitation     In2it Medical   Path to Wellness Integrated Health      Elevate Medical    Clecell co.,ltd Coastal Integrative Healthcare      RiverRun HEALTH      Selena University Specialised Hospital      TotalCare Health & Wellness      Amelie      City Health Services     Burick Center for Health & Wellness      Renew Medical Centers      La Estetica   Active Medicine Toronto      Chaparral Veterinary Medical Center      Tomsk National Research Medical Center      Protea Medical Center Desert Veterinary Clinic      Thrive Wellness Center      Active Healthcare  

𝐒𝐮𝐫𝐠𝐢𝐜𝐚𝐥 𝐒𝐮𝐭𝐮𝐫𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $5.5 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 Download PDF Brochure @ https://lnkd.in/dnJRYhcK The size of global 𝐬𝐮𝐫𝐠𝐢𝐜𝐚𝐥 𝐬𝐮𝐭𝐮𝐫𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 $4.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $5.5 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 6.4% from 2023 to 2028 The rise in #lifestylediseases due to the increasing adoption of a sedentary lifestyle is another factor contributing to the growth of #surgicalsutures. Lifestyle diseases such as #ischemicheartdiseases, #cerebrovascular diseases, #orthopedicdisorders, #cancers, and #mentalillness are constantly rising globally. This continuous rise in the prevalence of lifestyle diseases demands more surgical procedures, leading to the market growth of surgical sutures. The #US. accounted for #NorthAmerica's largest market share. This is due to strong #healthcareinfrastructure, extensive research and development activities, and the presence of major healthcare players and manufacturers within its borders. In addition, the U.S. healthcare system's emphasis on innovation, high healthcare expenditures, and favorable reimbursement policies further help its prominent share in the market. 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: Taisier Med for Surgical Sutures    Sutures India Pvt. Ltd     Medical Device France based MNC (CV and Surgical Sutures)      Medical Health Care International (Surgical Sutures and Ligatures)    Corza Medical      Universal Sutures      DemeTECH Corporation      Aurolab      Meditera        MZF4 Medical      Dolphin Sutures      Atramat® | Internacional Farmacéutica S.A. de C.V.      Katsan Medical Devices      Dogsan Surgical      Unilene SAC      Assut Europe      RESORBA Medical (Advanced Medical Solutions)      WEGO MEDICAL INTERNATIONAL CO.,LTD     WEGO Sutures   Phoenix Medicare Pvt Ltd    Ginos Group  Seevix Material Sciences  A.M. Distributors      BioSintex      Vitrex Medical A/S      Meta Biomed   Relyon Sutures - Bengaluru   Gabler Medical Vena Medical Supplies   Betatech Medical Orion Sutures (India) Private Limited  FEMSelect      Ophth Pharma Pvt. Ltd.      BIOMED™     Surgynique Engineering Solutions   AD Surgical    AUT Advanced Structures with Braid Technology Group      MediLive India     Oddway International      Medicamp Distributors   

Very interesting overview of radiopharmaceuticals market evolution

𝐑𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $49.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028 Download PDF Brochure @ https://lnkd.in/dPnCniRW The global 𝐫𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐦𝐚𝐫𝐤𝐞𝐭, 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 $16.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2023, 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $49.0 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2028, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 25.1%. The global market is expected to benefit from the focus on #personalizedmedicines. Precision medicine is an approach to medical treatment that tailors therapeutics, and interventions for individual patients or a subpopulation based on their unique genetic, environmental, and lifestyle characteristics. the 𝐅𝐃𝐀 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 12 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬, 𝐫𝐞𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐢𝐧𝐠 𝐚𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚𝐭𝐞𝐥𝐲 34% of all newly approved therapeutic molecular entities. Personalized treatments account for at least a quarter of new drug approvals since 2015. Moreover, five new gene or #cellbased therapies were approved in 2022. These include treatment of rare #geneticdisorders with few other treatment options – #betathalassemia, #hemophiliaB, and cerebral adrenoleukodystrophy, refractory multiple #myeloma, and certain types of non-muscle invasive #bladdercancer. 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: Cell Tissue Technology Sdn Bhd      Xellera Therapeutics        Mage Biotechnologies   ReLive Biotechnologies Limited      Institute of Biomedical Sciences      Śląski Park Technologii Medycznych Kardio-Med Silesia      Surecell      ALEXIS HOSPITAL     Medicus Spine & Joint      Regeneris Medical Boston      Third Space Medical    ARCALIS, Inc.    SCM Lifescience      RevitalyzeMD      ALGONE PREMIER      Bluetail Medical Group LLC     Integrative Health     DoctorsStudio    Pain Arthritis Relief Center      Babu™      MDBeautyLabs      Tantti Laboratory Inc.      iMAT     Axis Spine Center      Giostar Mexico     Clique Clinic      Connected Health Centers   Southern Inyo Healthcare District      MineBio Life Sciences Limited      Orizuru Therapeutics, Inc.      Care First Medical Center      LEBAO_MHH      American Animal Hospital     Iffat Anwar Medical Complex      Center for Wellbeing      Advanced Spine & Posture      REGEN HealthCare Sdn Bhd      Essential Health, PLLC      St. Luke's Medical Clinic and Wellness Center 

📈 𝗣𝗼𝘀𝘁-𝗗𝗶𝗮𝗹𝘆𝘀𝗶𝘀 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: 𝗔 𝗦𝗶𝗱𝗲-𝗯𝘆-𝗦𝗶𝗱𝗲 𝗖𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻 📉 Before, choosing an end-of-dialysis hemostatic solution was a game of chance. After, it became a game of facts and figures. 🎯 We're not ones to flex our muscles 💪, but we do believe in the power of performance. At NEPHROKIT, we respect our competitors and their technological choices. But we also believe in the power of comparison 📊, so you can make informed decisions based on objective criteria. When it comes to the key parameter - the time to complete clotting - here's how the 3 most common alternatives stack up: ▪ Standard cotton-based absorbent pad: 12.9 minutes (source: https://lnkd.in/dUZ45vrm) ▪ Hemostatic dressings (calcium alginate pads): 12.6 minutes (source: https://lnkd.in/dUZ45vrm) ▪ 𝘔𝘰𝘻𝘢𝘪𝘬™ (features NEPHROKIT microperforated technology): 5.8 minutes (source: Evamoz clinical study performed by the Association ECHO, carried out on 77 patients, presented at AFIDTN 2024) Do you think reducing the average clotting time by 7 minutes is a pipe dream? 🌫️ Think again. Drop a comment or send me a PM 💬, and I'll connect you with the nearest 𝘔𝘰𝘻𝘢𝘪𝘬™ distributor for free samples. Let the numbers speak for themselves. 🗣️ 💡 NEPHROKIT: We constantly innovate to improve hemodialysis patients' quality of care and life. 🏭 All NEPHROKIT devices are made in France by GERGONNE INDUSTRIE - THE ADHESIVE SOLUTION . #dialysis #hemodialysis #vascular #access #vascularaccess #nephrologist #nurses #patients #patientcare #coagulation #fistula #patch #plaster #dressing #hemostatic #wearenephrokit #wearegergonne #madeinfrance Mokhtar Chawki Medival S.r.l. Bionet Medical S.L. Theramed AG IVA Medical Hemotech Belux Bernas Médical Spirel AB Scan-Med A/S Denmark Scan-Med / NorDiaTech New EpiMed GenaMed Promamec Majestic Medical & Tech. Supplies

#TechForLicensing: Researchers at CCAMP in collaboration with DBT_CDFD Hyderabad have successfully developed & tested in mice a novel topical formulation that shows significantly accelerated complex wound healing through promoting regeneration of tissues! The Problem: The risk factor for complex foot ulcers is as high as 15-25% in diabetic patients as per a global study conducted in 2018. Efficient wound healing is a major challenge in the case of diabetic wounds/ foot ulcers, pressure ulcers, and venous leg ulcers. Impaired wound healing greatly impacts physical, psychological, social, and economic aspects for patients, affecting their quality of life, and even calling for amputations in certain difficult cases. Current Scenario: Frequent surgical debridement, antibiotic dressings, or recombinant growth factor injections are the solutions employed now. All have limitations ranging from the requirement of skilled medical personnel, secondary antimicrobial resistance, low efficacy and high cost. The new technology's performance: On a head-to-head with a marketed product, in-vivo data showed that the two proprietary components have significantly better: a) Wound healing b) Collagen deposition in diabetic animals. We believe it will also be useful in the treatment of other complex wounds like pressure ulcers and burns. We are inviting licensing interests. To know more, please reach out to the C-CAMP Office of Technology Transfer (#OTT): 📨 ott@ccamp.res.in ☎ 080 6718 5322 Taslimarif Saiyed, PhD Department of Biotechnology Office of the Principal Scientific Adviser to the Government of India Kris Gopalakrishnan Biotechnology Industry Research Assistance Council (BIRAC) Convatec Medtronic Digital Surgery Cardinal Health Smith+Nephew Integra LifeSciences Johnson & Johnson MiMedx Organogenesis 3M

Man 41a, with refractory abdominal pain in the right flank. Lithotripsy 4 years ago. Diuresis and kidney function preserved. CT/MRI scan showed a thrombus completely filling the lumen of the right renal vein with invasion of the vena cava/ delay in the concentration and excretion of the contrast, with significant edema of the kidney and adjacent adipose planes, compatible with congestion. Right kidney with increased dimensions in relation to the contralateral one, without hydronephrosis. Then full heparinization started. Tumor was ruled out. *This kidney would be at risk of failure in the medium to long term.* Therefore a suprarenal vena cava filter LifeTech™️ Technology Workshops was implanted and pharmacomechanical thrombectomy with 12cm catheter Ekos Boston Scientific Peripheral Interventions + Actilyse 0.8mg/h BIC device inside the thrombus for 24h. Next day completed the therapy by conventional and high-pressure balloon angioplasty, IVUS @Philips 18 Volcano and retrieval of the VCF. Presence of residual thrombus beams and septa, patent flow with excellent drainage without retention, irregular diameters along the vein. Discharged from hospital with Rivaroxaban Bayer | Pharmaceuticals 2 days later. Pain free, requested control Doppler.